the much bigger picture

Tucked away at the end of today’s announcement was a statement that I thought was of great potential significance.

In another significant development, Phosphagenics was recently notified of the allowance of a very broad patent in the United States for its proprietary patch by the United States Patent and Trademark Office.

Because I wanted to confirm my understanding, I contacted the company and Kathryn Harrison, VP of IP and Project Development has kindly and promptly replied.

In short, the claims of POH’s transdermal patch US patent application (Application No 20120201891, also referred to as US application no 13/501,500) have been examined and allowed. There are still a few procedural steps to go, including an inevitable fee to be paid, but, in essence, it’s all good to go.

POH has been allowed an incredibly broad range of claims, both with respect to the actives which are covered and the types of polymers which may be used to form the matrix. And if you are left in any doubt about how many applications of this patch are now covered by patent, check Claim 37. http://www.google.com/patents/EP2552486A1

POH's proprietary patch, now validated by impressive trial data, imo is literally priceless. Oxymorphone is merely a pharmaceutical amuse-bouche.